Colonics
About Me
Recent Posts
- Depression Doubles Risk Of Stroke In Middle-Aged Women
- Assessing The Efficacy Of Different Types Of Training Programs On Cognitive Performance In Elderly Patients
- Better Understanding Of Cells' Development Has Implications In Study Of Inflammatory Diseases
- How Much A Single Cell Breathes
- Insomnia Can Lead To Future Hospitalization And Increased Health Service Use
Menu
Calendar
| Mon | Tue | Wed | Thu | Fri | Sat | Sun |
|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | ||
| 6 | 7 | 8 | 9 | 10 | 11 | 12 |
| 13 | 14 | 15 | 16 | 17 | 18 | 19 |
| 20 | 21 | 22 | 23 | 24 | 25 | 26 |
| 27 | 28 | 29 | 30 | 31 | ||
Friends
Links
Entry 1 of 2682
Last Page | Next Page
3/10/2012
-
Zytiga Prednisone Combo Metastatic Castration-Resistant Prostate Cancer Trial Unblinded
|
A new aside by Janssen quest & Development, LLC informs that they have unblinded the Phase 3 study, COU-AA-302, which shows that Zytiga (abiraterone acetate), when taken beside prednisone, is productive in treating mildly symptomatic or asymptomatic work who are distress from metastatic castration-resistant prostate cancer (CRPC) and have not gone through chemotherapy. as concerned with Zytiga, which was approved by the U.S Food and Drug supervision (FDA) in 2011, William N. Hait, MD, PhD, from Global Head, Janssen R&D commented: "Since its first validate More: - From the site |
:: Send to a Friend! |
Share and enjoy
Report this!